Seven Mile Advisory Invests $738,000 in AstraZeneca PLC $AZNCF

Seven Mile Advisory purchased a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 4,207 shares of the company’s stock, valued at approximately $738,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Hughes Financial Services LLC acquired a new position in AstraZeneca during the fourth quarter valued at approximately $34,000. Mascoma Wealth Management LLC acquired a new position in shares of AstraZeneca during the 4th quarter valued at $46,000. Triumph Capital Management acquired a new position in shares of AstraZeneca during the 4th quarter valued at $75,000. Elyxium Wealth LLC purchased a new stake in AstraZeneca during the 4th quarter worth $102,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in AstraZeneca during the 4th quarter worth $122,000. 40.87% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

Shares of OTCMKTS AZNCF opened at $187.10 on Monday. The stock has a fifty day moving average price of $187.10 and a 200 day moving average price of $186.00. AstraZeneca PLC has a 12-month low of $122.26 and a 12-month high of $195.00.

About AstraZeneca

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.